Drug Trial Radar · NCT03900429
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,759
Actual
Start
Mar 28, 2019
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196Drug
Tablet
PlaceboDrug
Matching Tablets
Liver BiopsyProcedure
A procedure in which a needle is inserted into the liver to collect a tissue sample
Primary outcomes
What the sponsor says the trial is designed to measure.
- Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with BaselineTime frame: 52 weeks
- Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months)Time frame: up to 54 months
Locations
247 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
East Valley Family Physicians
Chandler, Arizona
The Institute for Liver Health - Chandler
Chandler, Arizona
The Institute for Liver Health - Glendale
Glendale, Arizona
Desert Clinical Research
Mesa, Arizona
Adobe Gastroenterology
Tucson, Arizona
The Institute for Liver Health - Tucson
Tucson, Arizona
Arkansas Gastroenterology
North Little Rock, Arkansas
Fresno Clinical Research Center
Fresno, California
National Research Institute - Huntington Park
Huntington Park, California
University of California San Diego
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
National Research Institute - Los Angeles
Los Angeles, California
Ruane Clinical Research
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
National Research Institute - Panorama City
Panorama City, California
Alliance Clinical Research
Poway, California
San Fernando Valley Health Institute
Van Nuys, California
Colorado Springs Family Practice
Colorado Springs, Colorado
South Denver Gastroenterology - Swedish Medical Center Office
Englewood, Colorado
Excel Medical Clinical Trials
Boca Raton, Florida
Covenant Metabolic Specialists - Fort Myers
Fort Myers, Florida
University of Florida Hepatology Research at CTRB
Gainesville, Florida
Nature Coast Clinical Research
Inverness, Florida
Florida Research Institute
Lakewood Rch, Florida
University of Miami
Miami, Florida
Miami Dade Medical Research Institute
Miami, Florida
Bioclinica Research - Orlando
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Covenant Research
Sarasota, Florida
Bioclinica Research - The Villages
The Villages, Florida
GI Specialists of Georgia
Marietta, Georgia
Clinical Research - Chicago
Chicago, Illinois
Northwestern Medical Faculty Foundation
Chicago, Illinois
The University of Chicago Medicine
Chicago, Illinois
University of Kansas Medical Center Research Institute
Fairway, Kansas
Kansas Medical Clinic - Gastroenterology
Topeka, Kansas
Texas Digestive Disease Consultants - Gastroenterology Associates - Baton Rouge
Baton Rouge, Louisiana
Tandem Clinical Research
Marrero, Louisiana
Tulane University School of Medicine
New Orleans, Louisiana
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.